Government ❯ Regulatory Agencies ❯ Securities and Exchange Commission ❯ Corporate Oversight

Investor Protection

Cytokinetics Faces Wave of Investor Lawsuits as Lead Plaintiff Deadline Nears

Plaintiffs allege Cytokinetics overstated its aficamten approval timeline by submitting an NDA without a REMS after FDA safety discussions.

KBR Investors Face Nov. 18 Lead-Plaintiff Deadline in Lawsuits Over HomeSafe Contract Fallout